First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

BACKGROUND: IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8(+ )T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brignone, Chrystelle, Gutierrez, Maya, Mefti, Fawzia, Brain, Etienne, Jarcau, Rosana, Cvitkovic, Frédérique, Bousetta, Nabil, Medioni, Jacques, Gligorov, Joseph, Grygar, Caroline, Marcu, Manon, Triebel, Frédéric
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2010
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2920252/
https://ncbi.nlm.nih.gov/pubmed/20653948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-71
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars